Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic, castration-resistant prostate cancer Age: Adult |
Dose: Tablet – 1 g (two 500-mg tablets or four 250-mg tablets) Frequency: once daily Note: In combination with prednisolone (5 mg by mouth every 12 hours) |
|
Indication: Metastatic high-risk castration-sensitive prostate cancer Age: Adult Condition: High-risk |
Dose: Tablet – 1000 mg (two 500-mg tablets or four 250-mg tablets) Frequency: every day Note: Administered by mouth with prednisone 5 mg by mouth every 12 hours; indicated in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer (CSPC) |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Tablet – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Mild-to-severe |
Dose: No dosage adjustment necessary Note: No dosage adjustment necessary for mild-to-severe renal impairment |
Administration
- Take on empty stomach
- Take 1 hour before or 2 hours after meals
Side Effect
- Hypertriglyceridemia (63%)
- Hyperglycemia
- nonfasting (57%)
- Increased ALT (11-46%)
- Fatigue (39%)
- Lymphopenia (20-38%)
- Increased AST (15-37%)
- Hypertension (8.5-37%)
- Hypernatremia (33%)
- Joint swelling/discomfort (30%)
- Hypokalemia (17-30%)
- Edema (25-27%)
- Muscle discomfort (26%)
- Hypophosphatemia (24%)
- Constipation (23%)
- Hot flush (15-22%)
- Diarrhea (18-22%)
- Hot flush (19%)
- Cough (6.5-17%)
- Increased total bilirubin (6.6-16%)
- Insomnia (14%)
- Contusion (13%)
- Upper respiratory tract infection (URTI) (5.4-13%)
- Urinary Tract Infection (UTI) (7-12%)
- Dyspnea (12%)
- Nasopharyngitis (11%)
- Dyspepsia (6.1-11%)
- Hypertension (1.3-20%)
- Hematuria (10%)
- Pyrexia (8.7%)
- Rash (8.1%)
- Headache (7.5%)
- Urinary frequency (7.2%)
- Arrhythmia (7.2%)
- Groin pain (6.6%)
- Nocturia (6.2%)
- Falls (5.9%)
- Fractures (5.9%)
- Chest pain or chest discomfort (3.8%)
- Cardiac failure (2.3%)
- Lymphopenia (4.1-8.7%)
- Hypophosphatemia (7.2%)
- Hyperglycemia
- nonfasting (6.5%)
- Increased ALT (1.4-6.1%)
- Hypokalemia (2.8-10%)
- Increased AST (2.1-4.4%)
- Joint swelling/discomfort (2-4.2%)
- Muscle discomfort (3%)
- Dyspnea (2.4%)
- Fatigue (2.2%)
- Urinary Tract Infection (UTI) (1-2.1%)
- Edema or cardiac failure(1.9%)
- Fractures (1.4%)
- Hematuria (1.3%)
- Arrhythmias (1.1%)
- Diarrhea (0.6-0.9%)
- Pyrexia (0.6%)
- Chest pain or discomfort (0.5%)
- Hypertriglyceridemia (0.4%)
- Groin pain (0.4%)
- Constipation (0.4%)
- Edema (0.4%)
- Hyponatremia (0.4%)
- Urinary frequency (0.3%)
- Hot flush (0.2-0.3%)
- Headache (0.3%)
- Upper respiratory tract (0.2%)
- Insomnia (0.2%)
- Increased total bilirubin (0.1-0.2%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Potassium-lowering drugs (e.g. Thiazide diuretics (Chlorothiazide, Chlorthalidone, Hydrochlorothiazide, Indapamide, Metolazone))
|
Increased risk of hypokalaemia
|
|
Spironolactone
|
Risk of tumour progression
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Hepatic Impairment
|
Risk of hepatotoxicity
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.